Advances in Inflammatory Bowel Diseases

P. Rutgeerts

ISBN 10: 0792387503 / ISBN 13: 9780792387503

Published by Springer, Springer Dez 1998, 1998

About this Item

This item is printed on demand - Print on Demand Titel. Neuware -Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease.The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 332 pp. Englisch.

Seller Inventory # 9780792387503

Bibliographic Details

• Title: Advances in Inflammatory Bowel Diseases
• Publisher: Springer, Springer Dez 1998
• Publication Date: 1998
• Language: English
• ISBN 10: 0792387503
• ISBN 13: 9780792387503
• Binding: Buch
• Condition: Neu
• Dimensions: 241W x 160H x 23D millimeters 241 millimeters width by 160 millimeters height by 23 millimeters depth
• Weight: 664 grams

About this title

Synopsis

Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease.
The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy.